Why EssilorLuxottica Fell Even As Profit Rose

Simply Wall St · 2d ago

EssilorLuxottica Société anonyme spent much of the past year in the headlines for family governance drama at Delfin and a series of share buybacks that signalled confidence from the board. Holding EssilorLuxottica Société anonyme over the past year would have meant a 41.5% loss, including dividends. If you had committed fresh capital on 13 November 2025, how should you now think about a business pushing into smart glasses, hearing support eyewear and medtech devices?

This theme extends beyond EssilorLuxottica Société anonyme. See which of 123 healthcare AI stocks may still merit a closer look.

The Two Stories EssilorLuxottica Investors Were Really Betting On

The shares cost €320 at the start of the period. Anyone buying EssilorLuxottica Société anonyme then had to choose between two very different stories about what that price already assumed.

The bullish narrative from February 2025, credited to User, argued for a Fair Value of €400, a target price implied by its own assumptions. That view leaned on 13.7% revenue growth and a future P/E of 57.0x, driven by smart glasses, Nuance Audio hearing eyewear and the Supreme acquisition.

The more cautious November 2025 case set Fair Value at €278 and projected 6.4% revenue growth with profit margins moving to 11.4%. It treated heavy spending on MedTech, AI glasses and premium eyewear as a real margin risk if economic or regulatory conditions turned less friendly.

ENXTPA:EL 1-Year Stock Price Chart
ENXTPA:EL 1-Year Stock Price Chart

What The Results Changed For EssilorLuxottica

EssilorLuxottica reported H1 2026 revenue of €14,818 million and net income of €1,566 million, with net margin moving to 10.6%. That outcome sat closer to the cautious case, which had foregrounded profitability discipline, although steady demand for AI glasses and Nuance Audio kept parts of the bullish expansion story alive.

The lesson is simple. When a thesis hinges on margin uplift, track net margin and absolute profit against the original forecast, not just headline growth stories or new product headlines.

What EssilorLuxottica’s Drop Left In Today’s Price

EssilorLuxottica Société anonyme now trades at €182 after a 41.5% loss over the past year, and the bullish analyst Narrative on Simply Wall St still places its Fair Value above that level based on its own assumptions.

That view leans on AI glasses, myopia care and oculomics centers gaining enough traction to turn wearables and medtech into meaningfully profitable pillars.

"The main thing that has to go right is that EssilorLuxottica Société anonyme turns its early traction in AI glasses, oculomics centers and global myopia solutions into scalable, profitable platforms across major regions despite rising competition and governance noise."

The price and this Narrative do not agree. → Uncover what this Narrative says EssilorLuxottica Société anonyme is actually worth

Looking One Step Beyond EssilorLuxottica

EssilorLuxottica is trying to turn eyewear into a medical device platform. If you care about that direction, it helps to look sideways.

Vision hardware still depends on a wider health system that can manage risk, pay claims and steer patients into appropriate care programs.

Another large operator focuses on that plumbing, using software, pharmacy services and data tools to run benefit plans and care models.

Its pitch is straightforward. Better clinical programs and AI-assisted workflows could trim waste, support steadier plan designs and reshape who captures more value from health spending.

That argument has a Narrative and a number behind it. → See the company one Narrative values 18% above its price